Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS) - van der Heijde, D; Dijkmans, B; Schiff, M; Kivitz, A; de Vlam, K; Wordsworth, P; Ballal, S; Kupper, H; Wong, R; Sieper, J; Grp, A (2008)